Phase i clinical studies study the effect of a drug on patients with the disease.
|
Brief Summary: Show This is a 4-week study to examine the effects of a new experimental medication on women with breast cancer and established bone metastases. This study will enroll approximately 45 women. The primary hypotheses are: (1) odanacatib will result in a substantial suppression of urinary N-telopeptide of type I collagen (u-NTx) similar to that achieved with an intravenous (IV) infusion of zoledronic acid (ZA) over 4 weeks of treatment; and (2) odanacatib (MK-0822) will be safe and well tolerated during 4 weeks of treatment.
Layout table for study information
Resource links provided by the National Library of Medicine 
Primary Outcome Measures :
Secondary Outcome Measures :
Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Layout table for eligibility information
Inclusion Criteria:
Exclusion Criteria:
Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00399802 Merck Sharp & Dohme LLC Layout table for investigator information
Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A, Lombardi A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010 Dec 1;10(6):452-8. doi: 10.3816/CBC.2010.n.059. Layout table for additonal information
Layout table for additional information
Additional relevant MeSH terms: Layout table for MeSH terms
What is Phase 1 of a clinical trial?A phase I clinical trial tests the safety, side effects, best dose, and timing of a new treatment. It may also test the best way to give a new treatment (for example, by mouth, infusion into a vein, or injection) and how the treatment affects the body.
What is the difference between Phase 1 and Phase 2 clinical trials?Phase 1: First testing in humans, primarily to test safety. A drug is given to a small number of healthy volunteers who are closely monitored. Phase 2: Testing in a small number of patients, to assess safety, to monitor how a drug is metabolized, and to gather initial data on efficacy.
What are the three things which happen in Phase 1 Clinical Trials?The main aim of phase 1 trials is to find out about doses and side effects. They need to do this first, before testing the potential new treatment to see if it works.. how much of the drug is safe to give.. what the side effects are.. what happens to the drug in the body.. if the treatment helps shrink the cancer.. What are Phase I II and III clinical trials?Phase I trials test if a new treatment is safe and look for the best way to give the treatment. Doctors also look for signs that cancer responds to the new treatment. Phase II trials test if one type of cancer responds to the new treatment. Phase III trials test if a new treatment is better than a standard treatment.
|
